Starting May 1, the groundbreaking cystic fibrosis medication, Trikafta, will be accessible to Australian children aged 6-11 through the Pharmaceutical Benefits Scheme (PBS).

Cystic fibrosis, a genetic disorder affecting 1 in 2,500 Australian newborns, results in the accumulation of thick mucus in the lungs and other organs.

With Trikafta’s inclusion on the PBS, over 500 children annually are anticipated to benefit, paying a maximum of $30 per prescription or $7.30 with a concession card. Without this subsidy, families could face annual costs exceeding $250,000 for the medication!

Jo Armstrong –  CEO of Cystic Fibrosis Australia said “this truly is a game-changer for the cystic fibrosis community.

Kate, the mother of a 3-year-old who suffers from CF thanked Ray for his support in an emotional call. “This drug adds 30 years to her life. You’ve done such an amazing job campaigning for it.”

Photo: Getty